microdose glp 1 benefits Microdosing GLP-1 Why GLP-1 Microdosing? A Closer

Safety of Semaglutide [published correction appears in Front Endocrinol (Lausanne)

Demi Moore, Nicole Kidman and Mindy Kaling are among the stars who showed off their slender physiques at some of the biggest events leading up to the 97th Academy Awards ceremony on Sunday

Clinical trial data provides objective evidence about efficacy (24.2% weight loss at 48 weeks), safety (88.8% completion rate), side effects (peak at weeks 6-8, resolve by week 12 for most), and discontinuation outcomes (70-80% regain over 12-18 months, not immediately)

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status